Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis Paz‐Ares, C. Chouaïd, Nicolas Girard et al.|Journal of Clinical Oncology|2024Cited by 126
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Heinz Gisslinger, Richard Greil et al.|British Journal of Haematology|2020Cited by 30
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to <100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Heinz Gisslinger, Jean‐Jacques Kiladjian et al.|Therapeutic Advances in Hematology|2022Cited by 11